Paolo Marchetti
Overview
Explore the profile of Paolo Marchetti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
435
Citations
6275
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Krasniqi E, Filomeno L, Arcuri T, Di Lisa F, Astone A, Cutigni C, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682290
Background/objectives: HER2-positive breast cancer (HER2BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been...
2.
Filetti M, Occhipinti M, Cirillo A, Scirocchi F, Ugolini A, Giusti R, et al.
Cancers (Basel)
. 2024 Dec;
16(23).
PMID: 39682144
: Single-agent immune checkpoint inhibitor (IO) therapy is the standard for non-oncogene-addicted advanced non-small cell lung cancer (aNSCLC) with PD-L1 tumor proportion score ≥ 50%. Smoking-induced harm generates high tumor...
3.
Verkhovskaia S, Falcone R, Di Pietro F, Carbone M, Samela T, Perez M, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39410017
Background: When monotherapy with PD-1 inhibitors in metastatic melanoma fails, there are currently no standard second-line choices. In case of the unavailability of clinical trials, ipilimumab represents a possible alternative...
4.
Di Pietro F, Marinelli D, Verkhovskaia S, Poti G, Falcone R, Carbone M, et al.
BMC Cancer
. 2024 Oct;
24(1):1220.
PMID: 39354418
Immunotherapy with anti-PD-1 antibodies significantly improved the prognosis in advanced melanoma patients, but most of them develop primary or secondary resistance to the treatment. In this study, we evaluated efficacy...
5.
Di Pietro F, Verkhovskaia S, Falcone R, Poti G, Carbone M, Morelli M, et al.
Front Oncol
. 2024 Aug;
14:1437325.
PMID: 39148899
Background: Stage III surgically resected melanoma is a disease at high risk of recurrence. Immune checkpoint inhibitors (ICIs) and the target therapy with BRAF and MEK inhibitors significantly changed the...
6.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, et al.
NPJ Breast Cancer
. 2024 Aug;
10(1):68.
PMID: 39095493
No abstract available.
7.
Scagnoli S, Pisegna S, Toss A, Caputo R, De Laurentiis M, Palleschi M, et al.
NPJ Breast Cancer
. 2024 Jul;
10(1):58.
PMID: 39019916
Abemaciclib demonstrated clinical benefit in women affected by HR+/HER2- advanced breast cancer (aBC). Drug-drug interactions (DDIs) can lead to reduced treatment efficacy or increased toxicity. This retro-prospective study aimed to...
8.
Cirillo A, Marinelli D, Romeo U, Messineo D, De Felice F, de Vincentiis M, et al.
BMC Cancer
. 2024 Apr;
24(1):487.
PMID: 38632499
No abstract available.
9.
Cirillo A, Marinelli D, Romeo U, Messineo D, De Felice F, de Vincentiis M, et al.
BMC Cancer
. 2024 Apr;
24(1):430.
PMID: 38589857
Background: The KEYNOTE-048 trial showed that pembrolizumab-based first-line treatment for R/M HNSCC led to improved OS in the PD-L1 CPS ≥ 1 population when compared to the EXTREME regimen. However,...
10.
Di Giacomo A, Chiarion-Sileni V, Del Vecchio M, Ferrucci P, Guida M, Quaglino P, et al.
Eur J Cancer
. 2024 Mar;
202:113981.
PMID: 38461074
No abstract available.